Clinical comparison of erlotinib and gefitinib in non-small cell lung cancer with brain metastases

Chinese Journal of Cancer Prevention and Treatment

Volumn 22, Issue 4, 2015, Pages 285-288

  Zhang, Jie Xia ^a   Cai, Di ^a   Li, Shi Yue ^a   Zhou, Cheng Zhi ^a   Qin, Yin Yin ^a   Ouyang, Ming ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Brain metastases; EGFR mutation; NSCLC; Targeted therapy

Indexed keywords

ERLOTINIB; GEFITINIB; VASCULOTROPIN;

ARTICLE; BRAIN METASTASIS; CONTROLLED STUDY; DRUG EFFICACY; EXON; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84922602625     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Youlden DR, Cramb SM, Baade PD, et al. The International Epidemiology of Lung Cancer: geographical distribution and secular trends[J]. J Thorac Oncol, 2008, 3(8): 819-831.
2. Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR. 21 trial[J]. J Thorac Oncol, 2012, 7(11): 1653-1660.
3. Zhou S, Ren S, Yan L, et al. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer[J]. Respirology, 2009, 14(5): 709-715.
4. Weber B, Winterdahl M, Memon A, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor[J]. J Thorac Oncol, 2011, 6(7): 1287-1289.
5. Zhao J, Chen M, Zhong W, et al. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma[J]. Clin Lung Cancer, 2013, 14(2): 188-193.
6. Li Z, Lu J, Zhao Y, et al. The retrospective analysis of the frequency of EGFR mutations and efficacy of gefitinib in NSCLC patients with brain metastases[J]. J Clin Oncol, 2011, 29: e18065.
7. Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma[J]. Lung cancer, 2013, 82(2): 282-287.
8. Park SJ, Kim HT, Lee DH, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation[J]. Lung cancer, 2012, 77(3): 556-560.
9. Wu YL, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in pdatients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)[J]. Ann Oncol, 2013, 24(4): 993-999.
10. Khimani NB, Ng AK, Chen YH, et al. Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy[J]. Ann Oncol, 2011, 22(4): 979-984.